Core Insights - The 2025 Hurun China Brand List was released, marking the 20th edition of the list, which now includes non-Chinese brands that serve Chinese consumers for the first time [1][6] - Apple tops the list with a brand value of 1.11 trillion RMB, followed by Kweichow Moutai at 795 billion RMB, and WeChat at 325 billion RMB, which saw the highest growth among Chinese brands [4][5] Brand Rankings - The top five brands are: 1. Apple - 1,110 billion RMB (USA, Consumer Electronics) [4] 2. Kweichow Moutai - 795 billion RMB (China) [4] 3. WeChat - 325 billion RMB (China, +38%) [4] 4. Douyin - 280 billion RMB (China, +14%) [4] 5. Tesla - 270 billion RMB (USA, New Entry) [4] Industry Insights - The consumer electronics sector has surpassed the liquor industry to become the highest-valued industry on the list, while liquor remains the highest-valued industry for domestic brands [5] - A total of 386 brands from China made the list, leading the rankings, followed by 46 from the USA and 19 from France [5] Regional Highlights - Hunan province has six brands on the list, including Furong Wang at 18th, Aier Eye Hospital at 131st, and Mango TV at 214th [5] - Shanghai is the city with the most brands on the list, contributing 136 brands, followed by Beijing with 104 [5] New Entries - 212 new brands were added to the list, primarily from the food and beverage and daily chemical industries, with notable entries like Red Bull and Coca-Cola [5][6] - The automotive sector also saw significant new entries, including Tesla and Toyota [5] Brand Value Growth - The total brand value of the listed brands reached nearly 8.8 trillion RMB, an increase of 47% from the previous year [6] - The thresholds for the top 300, 200, and 100 brands have increased, indicating a rise in brand value requirements [6]

Group 1 - The core viewpoint of the news highlights the positive performance of the medical innovation sector, with the CSI Medical and Medical Device Innovation Index showing mixed results among its constituent stocks, led by Aimeike with a 2.18% increase [1] - The Medical Innovation ETF has seen continuous net inflows over the past 12 days, with a peak single-day net inflow of 41.83 million yuan, totaling 234 million yuan, averaging 19.54 million yuan per day [1] - Policy support for the pharmaceutical industry is ongoing, with Shanghai accelerating the implementation of major industrial projects in fields such as integrated circuits, biomedicine, and artificial intelligence [1] Group 2 - The CSI Medical and Medical Device Innovation Index consists of 30 listed companies with good profitability, growth potential, and research innovation capabilities, reflecting the overall performance of profitable and growth-oriented pharmaceutical and medical device companies [2] - As of January 30, 2026, the top ten weighted stocks in the index include WuXi AppTec, Mindray Medical, and Heng Rui Medicine, accounting for 63.9% of the total index weight [2] - The success rate of Phase I clinical trials for dozens of AI-derived pipelines entering trials in 2025 is projected to be as high as 80%-90%, significantly exceeding traditional levels of 40%-65% [1]

发布时间：2026-02-02 行业投资评级 强于大市|维持 | 行业基本情况 | | | --- | --- | | 收盘点位 | 8338.3 | | 52 周最高 | 9323.49 | | 52 周最低 | 6876.88 | 行业相对指数表现 -5% -1% 3% 7% 11% 15% 19% 23% 27% 31% 2025-02 2025-04 2025-06 2025-09 2025-11 2026-01 医药生物 沪深300 资料来源：聚源，中邮证券研究所 研究所 分析师:盛丽华 SAC 登记编号:S1340525060001 Email:shenglihua@cnpsec.com 分析师:徐智敏 SAC 登记编号:S1340525100003 Email: xuzhimin@cnpsec.com 近期研究报告 2025 年有数十个 AI 衍生的管线进入人体临床试验，但回顾过往 管线来看，与任何其他新技术的发展一样，AI 制药的发展之路也是曲 折的。AI 制药极大加速了临床早期的进程同时亦能取得超出传统经验 水平的 1 期成功率（80%~90% vs 40%~65%），而在 2 期及后续的进 ...

消息面上，2月1日，华为云正式宣布，"行业AI梦工厂"首个落地成果——智慧医疗专区亮相，同时，即 日起启动公开测试，率先开放健康管理与病理AI辅助诊断两大核心功能，面向广大医疗机构、医生及 大众开放服务与体验。该专区深度融合上海瑞金医院等顶尖医疗机构的临床经验与华为在云、AI及ICT 领域的技术积累，旨在构建一个端到端的AI赋能平台。 光大证券强调，在医保控费（DRG/DIP）与大模型技术奇点双重驱动下，AI已成为医疗新基建的核心 生产力；其中AI制药因能显著缩短研发周期、药企付费意愿最强，AI医学影像是当前落地最成熟的赛 道，而AI慢病管理和AI手术机器人则分别依托商业保险降本逻辑与医疗资源均衡逻辑，具备强国产化 替代潜力。未来竞争核心在于独家高质量私有数据与业务场景闭环能力。 医疗创新ETF紧密跟踪中证医药及医疗器械创新指数，中证医药及医疗器械创新指数从医药卫生行业的 上市公司中，选取30只盈利能力较好且具备一定成长性和研发创新能力的上市公司证券作为指数样本， 以反映兼具盈利性与成长性的医药及医疗器械上市公司证券的整体表现。 截至2026年2月2日 10:44，中证医药及医疗器械创新指数(931484)下 ...

本周医药板块表现弱于整体市场，医药商业降幅居前。本周全部 A 股下 跌 0.98%（总市值加权平均），沪深 300 上涨 0.08%，中小板指下跌 3.78%，创业板指下跌 0.09%，生物医药板块整体下跌 3.31%，生物医 药板块表现弱于整体市场。分子板块来看，化学制药下跌 3.20%，生物 制品下跌 2.50%，医疗服务下跌 4.15%，医疗器械下跌 3.86%，医药商 业下跌 4.49%，中药下跌 1.94%。医药生物市盈率（TTM）37.27x，处 于近 5 年历史估值的 80.47%分位数。 精锋医疗为领先的手术机器人公司。精锋医疗成立于 2017 年，是中国 首家、全球第二家同时取得多孔腔镜、单孔腔镜及自然腔道三类手术机 器人注册审批的领先企业，2024 年斩获国内手术机器人制造商销量第 一，2026 年 1 月于香港联交所挂牌上市。公司核心管理层具备深厚的 行业经验与国际背景，全球专利布局超 734 项，技术实力雄厚。 精锋医疗构建了覆盖多科室的丰富管线。多孔系列 MP1000 及升级款 已获批多专科应用并实现商业化放量，单孔系列 SP1000 为国内首个 覆盖三大外科的国产单孔机器人，支气管 ...

Investment Rating - The report maintains an "Outperform" rating for the pharmaceutical and biotechnology sector [4] Core Insights - The surgical robot market is expected to grow significantly, driven by technological innovation, clinical demand, and policy benefits, particularly in China where the penetration rate is projected to increase from 0.7% in 2024 to 3.0% by 2033 [20][29] - Jingfeng Medical is a leading surgical robot company in China, having achieved significant milestones including the first domestic sales ranking in 2024 and a successful listing on the Hong Kong Stock Exchange in January 2026 [1][10] - The company has a robust pipeline of products across multiple specialties, with its multi-port and single-port surgical robots already commercialized and showing strong sales growth [2][34] Summary by Sections Market Performance - The overall pharmaceutical sector underperformed the market, with a decline of 3.31% in the biopharmaceutical sector, while the A-share market saw an average decline of 0.98% [1] - The TTM price-to-earnings ratio for the biopharmaceutical sector stands at 37.27x, which is at the 80.47th percentile of the past five years [1] Company Overview - Jingfeng Medical was established in 2017 and is the first in China and the second globally to obtain regulatory approval for multi-port, single-port, and natural orifice surgical robots [10] - The company has over 734 global patents, showcasing its strong technological capabilities and commitment to innovation [35] Product Pipeline - The company has developed a diverse product line, including the MP1000 multi-port robot and the SP1000 single-port robot, which are approved for various surgical applications [2][10] - The CP1000 bronchoscopic robot is an innovative product aimed at non-invasive diagnosis and treatment of lung diseases, with significant clinical advantages [31][34] Financial Projections - Jingfeng Medical's revenue for the first half of 2025 reached 149 million RMB, a year-on-year increase of 394%, with surgical robot sales accounting for 92.9% of total revenue [34] - The company is expected to continue its growth trajectory with increasing overseas orders and expanding market presence [35] Competitive Landscape - The multi-port surgical robot market is currently dominated by Intuitive Surgical, which holds an 83% market share, while domestic competitors are rapidly emerging [26] - The single-port robot market is still in its early stages, with Jingfeng Medical holding a first-mover advantage in China [28]

Investment Rating - The report maintains a "Buy" rating for the medical services industry [6][10]. Core Insights - The medical and biological sector experienced a decline of 3.31% this week, ranking 22nd among the 31 primary industries in the Shenwan index. The Shanghai and Shenzhen 300 index rose by 0.08%, indicating that the medical sector underperformed by 3.39 percentage points [2][12]. - The newly revised "Regulations on the Implementation of the Drug Administration Law" will take effect on May 15, 2026, aiming to enhance drug research, registration, and production management, thereby fostering innovation in the pharmaceutical industry [5][61]. - The medical services sector's current Price-to-Earnings (PE) ratio is 33.87X, with a Price-to-Book (PB) ratio of 3.43X, reflecting a decrease from the previous week [4][30]. Summary by Sections Industry Performance - The medical services sub-sector closed at 7122.75 points, down 4.15% this week, while the overall medical and biological sector fell by 3.31% [2][24]. - Notable performers in the medical services sector included Tigermed (+4.3%) and Prasis (+2.3%), while underperformers included Bid Pharma (-15.2%) and Haoyuan Pharma (-12.8%) [3][28]. Valuation Metrics - The medical services sector's PE ratio has decreased by 1.43X from the previous week, while the PB ratio has dropped by 0.15X [4][30]. - The maximum and minimum PE ratios over the past year were 41.13X and 28.46X, respectively, while the PB ratios ranged from 4.00X to 2.48X [30][49]. Regulatory Developments - The new drug administration regulations aim to support drug innovation and streamline the drug approval process, including provisions for market exclusivity for certain drugs [5][63]. - The regulations are expected to stimulate the CXO (Contract Research Organization) industry, enhancing demand for preclinical research and clinical trials [9][63]. Investment Recommendations - The report suggests focusing on high-growth areas such as ADC CDMO and peptide CDMO companies like WuXi AppTec and Haoyuan Pharma, as well as companies in the consumer healthcare sector like Aier Eye Hospital and Dian Diagnostics, which are expected to see improvements in profitability [10][64].

Group 1 - The pharmaceutical sector experienced a pullback, with the pharmaceutical ETF (159929) declining by 1.53% and a trading volume exceeding 1.3 billion yuan, indicating a net inflow of over 45 million yuan during the day, marking 11 consecutive days of capital inflow totaling over 360 million yuan [1][3] - Major stocks within the pharmaceutical ETF saw most decline, including Meien Health and Pianzaihuang dropping over 3%, WuXi AppTec and Aier Eye Hospital falling over 2%, while Tigermed rose over 7% [3][4] - Tigermed is projected to see a net profit growth of 105% to 204% by 2025, indicating strong future performance [3] Group 2 - The JPM 2026 conference highlighted a shift in the global pharmaceutical industry's focus towards the effective allocation and long-term value realization of innovations amidst rising uncertainties [5] - Chinese innovation is gaining global recognition, with increased participation from Chinese companies at the JPM 2026, reflecting a growing acknowledgment from international capital and multinational pharmaceutical companies [5][6] - The evaluation logic of multinational pharmaceutical companies regarding Chinese innovative assets is evolving, focusing on their efficacy, differentiation, and competitive positioning for inclusion in global product portfolios [6][10] Group 3 - Multinational pharmaceutical companies are entering a critical patent cliff period, necessitating diversification in their pipelines to mitigate risks associated with single products and treatment areas [10][12] - The integration of AI into core strategies is becoming mainstream, with AI being utilized to enhance R&D efficiency and optimize operational systems, thus addressing challenges posed by the patent cliff [12][13] - The oncology sector remains a core area for pharmaceutical innovation, with a focus on antibody-drug conjugates (ADCs) and cell therapies, indicating a robust pipeline and commercial potential [13][15]

Summary of Key Points from Conference Call Records Industry Overview - **General Economic Outlook**: The Chinese economy shows signs of stabilization, with nominal GDP growth expected to enhance corporate profits. Supply contraction outpacing demand may improve industry prices and corporate earnings, highlighting opportunities in cyclical industries [1][2][3]. Real Estate Sector - **Investment Value**: The real estate sector is deemed to have high investment value, with significant growth in second-hand housing transaction volumes and a narrowing decline in listing prices. Major cities like Beijing and Shanghai have seen listing volumes drop by over 15% [1][3]. - **Policy Catalysts**: Continuous policy support for real estate investment trusts (REITs) and other measures are expected to catalyze the market. The valuation of real estate stocks is considered to have a sufficient margin of safety, with many leading companies trading at a price-to-book (PB) ratio significantly below 1 [1][3][11]. - **Market Dynamics**: The short-term data indicates positive changes in the real estate market, with a notable decrease in listings for older urban properties, as owners prefer renting or waiting for redevelopment rather than selling at lower prices [4][5]. Travel and Transportation Sector - **Positive Outlook**: The travel industry is expected to benefit from government policies promoting tourism, with signs of recovery in duty-free and hotel sectors. The airline industry anticipates strong growth in passenger traffic, with ticket prices expected to be higher than last year [1][8][9]. - **Airline Performance**: During the 2026 Spring Festival travel period, the airline industry is projected to see a 5-6% increase in passenger traffic, with improved ticket pricing compared to 2025. The industry is entering a positive development phase, with a supply growth rate of about 4% and demand growth of approximately 5.5% [9]. Home Appliance Sector - **Investment Opportunities**: The home appliance sector is currently undervalued, presenting good investment opportunities across various segments, including kitchen appliances and white goods. Leading companies are expected to maintain stable performance and high dividend payouts [1][10][11]. Coal Industry - **Market Conditions**: The coal industry is experiencing a marginal improvement in supply-demand dynamics, with a stable price recovery expected. Supply constraints are anticipated to reduce domestic coal supply by 70 million to 100 million tons in 2026, while demand remains resilient [2][19][20]. Chemical Industry - **Future Trends**: The chemical industry is gaining attention due to increased market liquidity and expectations of positive producer price index (PPI) trends. Supply-side constraints and improved demand from global markets are expected to drive price increases [17][18]. Consumer Healthcare Sector - **Recovery Signs**: The consumer healthcare sector is showing early signs of stabilization, particularly in ophthalmology and dental services. Key players in these segments are expected to benefit from a recovering market environment [16]. Food and Beverage Sector - **Market Performance**: The food and beverage sector has seen significant price increases, particularly for premium brands like Moutai. However, potential risks include the release of pent-up supply post-holiday, which could impact prices [21][22]. Construction and Building Materials - **Market Changes**: The construction materials sector is adapting to a shift in demand from new housing to renovations of existing properties. Recent data indicates a recovery in demand for glass and other materials, with expectations of price stabilization and potential increases [24][25]. Conclusion - **Investment Strategy**: Overall, the cyclical industries, particularly real estate, travel, and home appliances, present promising investment opportunities. The focus should be on companies with strong fundamentals and favorable market conditions as the economy stabilizes [1][3][8][11].

消息面上，民政部印发《关于进一步推进民政科技创新的指导意见》，其中提到，广泛应用人形机器 人、脑机接口、人工智能等前沿技术，开展失能失智预防和抗衰老、生活照料和康复护理、精神慰藉和 社会参与促进、安全风险监测和紧急救援、老年宜居环境建设和适老化改造等方面关键技术装备研发。 截至2026年1月30日 10:05，中证医药及医疗器械创新指数(931484)成分股方面涨跌互现，海思科领涨 2.62%，新产业上涨1.67%，华润三九上涨0.96%；片仔癀领跌。医疗创新ETF(516820)最新报价0.36元。 规模方面，医疗创新ETF最新规模达18.67亿元，创近1年新高。从资金净流入方面来看，医疗创新ETF 近10天获得连续资金净流入，最高单日获得4182.65万元净流入，合计"吸金"1.86亿元，日均净流入达 1857.56万元。（数据来源：Wind） 招商证券指出，脑机接口技术已从长期学术探索阶段进入产业拐点，在政策与需求双重驱动下，医疗成 为其核心主战场，占全球应用场景的56%；中国脑机接口产业在系统集成与应用落地方面进展显著， 2025年被正式纳入"十五五"规划中的"六大未来产业"，顶层设计与地方支持同步加 ...